Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuel Raschi

Showing results (21-30 of 213) with videos related to

Pageof 22
Sort By:
Current Drug Targets|December 4, 2010
Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodelingEmanuel Raschi, Giuseppe Boriani, Fabrizio De Ponti
Clinical Pharmacokinetics|February 28, 2015
Comment on: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus"Emanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
Journal of the American Academy of Dermatology|December 11, 2024
Comment on "Evaluation of anticancer therapy-related dermatologic adverse events: Insights from Food and Drug Administration's adverse event reporting system dataset"Emanuel Raschi, Michelangelo La Placa, Michela Starace
The Lancet. Oncology|December 1, 2022
QT prolongation with anticancer drugs: a multimodal issueEmanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 8, 2021
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysisMilo Gatti, Emanuel Raschi, Fabrizio De Ponti
Clinical Pharmacology and Therapeutics|April 1, 2025
Chat GPT and the Challenges to Detect Potential Drug-Drug Interactions Related to QT ProlongationEmanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
Clinical Pharmacology and Therapeutics|May 30, 2023
Interpretation of Pharmacovigilance Disproportionality AnalysesCharles Khouri, Michele Fusaroli, Francesco Salvo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 27, 2023
Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical IssueFrancesco Gelsomino, Giovanni Vitale, Emanuel Raschi, et al.
Drug Safety|February 24, 2021
Authors' Reply to Robert P. Giugliano and Colleagues' Comment on: "Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance"Emanuel Raschi, Michele Fusaroli, Igor Diemberger, et al.
Expert Opinion on Drug Safety|June 24, 2024
The evolving role of disproportionality analysis in pharmacovigilanceMichele Fusaroli, Emanuel Raschi, Elisabetta Poluzzi, et al.
Pageof 22

Showing results (21-30 of 213) with videos related to

Sort By:
Pageof 22
Current Drug Targets|December 4, 2010
Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodelingEmanuel Raschi, Giuseppe Boriani, Fabrizio De Ponti
Clinical Pharmacokinetics|February 28, 2015
Comment on: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus"Emanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
Journal of the American Academy of Dermatology|December 11, 2024
Comment on "Evaluation of anticancer therapy-related dermatologic adverse events: Insights from Food and Drug Administration's adverse event reporting system dataset"Emanuel Raschi, Michelangelo La Placa, Michela Starace
The Lancet. Oncology|December 1, 2022
QT prolongation with anticancer drugs: a multimodal issueEmanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 8, 2021
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysisMilo Gatti, Emanuel Raschi, Fabrizio De Ponti
Clinical Pharmacology and Therapeutics|April 1, 2025
Chat GPT and the Challenges to Detect Potential Drug-Drug Interactions Related to QT ProlongationEmanuel Raschi, Elisabetta Poluzzi, Fabrizio De Ponti
Clinical Pharmacology and Therapeutics|May 30, 2023
Interpretation of Pharmacovigilance Disproportionality AnalysesCharles Khouri, Michele Fusaroli, Francesco Salvo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 27, 2023
Severe Liver Injury Triggered by Sequential Use of Immune Checkpoint Blockers and Tyrosine Kinase Inhibitors: An Emerging Clinical IssueFrancesco Gelsomino, Giovanni Vitale, Emanuel Raschi, et al.
Drug Safety|February 24, 2021
Authors' Reply to Robert P. Giugliano and Colleagues' Comment on: "Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance"Emanuel Raschi, Michele Fusaroli, Igor Diemberger, et al.
Expert Opinion on Drug Safety|June 24, 2024
The evolving role of disproportionality analysis in pharmacovigilanceMichele Fusaroli, Emanuel Raschi, Elisabetta Poluzzi, et al.
Pageof 22